Logotype for Chimeric Therapeutics Ltd

Chimeric Therapeutics (CHM) investor relations material

Chimeric Therapeutics Investor Update summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Chimeric Therapeutics Ltd
Investor Update summary8 Oct, 2025

CHM CDH17 clinical program update

  • Phase 1 trial of autologous CAR-T targeting CDH17 is ongoing at four major US sites, with IND cleared in Nov 2023 and fast track designation achieved in April 2024.

  • Eight patients have been treated, with 10/10 successful GMP manufacturing runs and no safety issues or off-target effects observed.

  • Tumor shrinkage up to 37% and stable disease have been observed in several patients, with one patient showing stable disease at 10 months.

  • Dose level 1 is completed, dose level 2 recruitment is ongoing, and dose level 3 recruitment is underway.

  • Phase 1 is nearing completion, with Phase 2 to begin without further FDA review; orphan drug designation is under review.

CHM CORE-NK clinical program update

  • CHM CORE-NK is an off-the-shelf allogeneic NK cell therapy, manufactured from universal donors, with up to 200 doses per donor.

  • Investigator-initiated trials at MD Anderson and Case Western are ongoing, with MD Anderson leading a frontline AML study combining CORE-NK with azacitidine and venetoclax.

  • Seven patients treated in the frontline study, with four complete responses and one partial response; no safety issues observed.

  • Dose escalation is complete, and first-line dosing is underway, aiming for up to 20 patients.

  • Full data readout expected mid-next year, with ongoing updates planned.

Commercial and regulatory outlook

  • Significant commercial interest in CDH17 asset due to large market size and unique CAR-T approach; multiple partnership discussions ongoing.

  • Manufacturing capacity gaps at major pharma present opportunities for scaling.

  • Regulatory path for CDH17 may allow for Phase 2 registration, following precedent in cell therapy approvals.

  • Orphan drug designation for CDH17 is under review; no designation yet for CORE-NK.

  • The global market size for target indications is estimated at $27.7B in 2024.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Chimeric Therapeutics earnings date

Logotype for Chimeric Therapeutics Ltd
H1 202626 Feb, 2026
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Chimeric Therapeutics earnings date

Logotype for Chimeric Therapeutics Ltd
H1 202626 Feb, 2026

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Chimeric Therapeutics Ltd is a biotechnology company focused on developing cell therapy treatments for cancer. The company specializes in chimeric antigen receptor T-cell (CAR-T) therapies, aiming to harness the immune system to target solid tumors and hematologic malignancies. The company is headquartered in Melbourne, Australia, and its shares are listed on the ASX.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage